Quentin Le Masne de Chermont’s Post

📢 Exciting Announcement: We're thrilled to share that Crohn’s Colitis Cure (CCCure) has entered into a strategic partnership with a 'Top 5' Global Pharma company for our revolutionary IBD patient data platform, Crohn’s Colitis Care (CCCare). This partnership marks a significant milestone in advancing IBD research and development, expected to accelerate the development of innovative therapies and improve patient care. Read the full media release below! ⬇️ #IBDResearch #HealthTech #PatientCare #MedicalInnovation #PharmaPartnership #CrohnsColitisCare #HealthData #CrohnsDisease #UlcerativeColitis #InflammatoryBowelDisease #IBDCommunity #Gastroenterology #HealthcareTechnology #PatientCentricCare #ResearchAndDevelopment #HealthcarePartnerships #MedicalResearch #ChronicIllness #DataAnalytics #HealthcareAdvancement #HealthTechInnovation #HealthcareInnovation #CrohnsColitisCure

April 26, 2024 - MNC Capital Inc. represents Elixia, LLC in the transformative divestiture to Latticework Capital Management's portfolio company, American Clinical Research Services Holding, LLC ("ACRS"). Elixia is a distinguished multi-specialty clinical research network with operations spanning Florida, Massachusetts, Michigan, and Missouri. Elixia has carved a niche in tackling complex clinical challenges across nephrology, neuroscience, and infectious diseases, with a notable specialization at its 40-bed Phase I unit in Tampa, Florida, focused on renal and hepatically impaired patients. ACRS, formed by Latticework Capital Management LLC, is a Dallas, Texas-based industry-leading clinical research entity. ACRS links a vast network of multi-site clinical research facilities with a global patient recruitment operation, conducting Phase I-IV studies. ACRS' strategic acquisition of Elixia amplifies their shared commitment to advancing research in challenging therapeutic areas like nephrology, neuroscience, and infectious diseases. This union enhances their resources, expands their site capabilities across multiple states, and improves their ability to launch and sustain studies that can significantly enhance patient outcomes. The successful execution of MNC Capital's sell-side process for Elixia has resulted in the company finding the ideal partner, American Clinical Research Services Holding, LLC, for their next phase of continued success, while maximizing both shareholder value and Elixia's enterprise value. #mergersandacquisitions #privateequity #clinicaltrialresearch #clinicaltirals #clinicalresearch #pharmaservices #pharmaceuticalindustry

As we continue to forge ahead with our new partnership with AstralBio, the enthusiasm within and around our teams is palpable. Following our initial announcement, it's time to spotlight the remarkable expertise that Martin Brenner, iBio's CEO and CSO, brings to this venture, especially in cardiometabolic disease research. With a career that spans industry giants like Eli Lilly and Pfizer, Martin's contributions to obesity and cardiometabolic disease drug development have been nothing short of revolutionary. His words resonate with our mission: "Leveraging my experience in obesity and cardiometabolic disease drug development from my time at Eli Lilly and Pfizer, I am eager to advance potentially groundbreaking compounds through our partnership with AstralBio." Martin's expertise is a testament to iBio's strategic approach, which is focused on tackling some of the most challenging healthcare issues facing the world today. His vision and deep understanding of the intricacies of developing therapies for obesity and cardiometabolic diseases are invaluable as we collaborate with AstralBio. Together, we aim to create therapies and revolutionize how these conditions are treated globally. This partnership is a testament to our unwavering commitment to leveraging unparalleled expertise and innovative technologies to develop therapies that can profoundly impact patients' lives. With Martin Brenner leading iBio's scientific endeavors, we are more confident than ever in achieving extraordinary outcomes that will make a real difference to patients worldwide. #iBio #AstralBio #Biotech #Collaboration #CardiometabolicHealth #DrugDevelopment

The next big thing 🔬 Being the largest dedicated #healthcare investment trust in the world, with a total AUM of $2.7 billion, with key themes driving stocks higher and maintaining a strong investment position in the sector; the team is always searching for the next big thing in the healthcare space. One of the key ingredients for the long-term growth of the trust over the last 28 years has been #innovation. Since its inception in 1995, Worldwide Healthcare Trust has been at the forefront of investing in upcoming and innovative medicines, clinical trials, and university start-ups. Sven Borho, co-manager of WWH, believes that the ‘recipe for success’ is the trust’s focus on the most innovative and highest-growth companies on the horizon. He highlights that while this approach may cause some volatility in the short-term, it is the strongest method for growth and out-performance of their global benchmark (MSCI World Index). By championing innovation, the trust can get ahead of the #PatentCliffs of many products, on average peaking every 10 years. With the next ‘looming patent cliff’ due by the end of the decade, it has seen the pipeline for new innovative products increase by 70% since 2016 . These products will be the key drivers for the new wave of ‘mega blockbuster’ drugs, replacing the current top multibillion-dollar revenue generators, of which Sven remarks this as ‘the changing of the guard.’  Several front-runners & exciting developments are well-positioned within the portfolio. The three main categories that have shown positive results in recent clinical trials include #oncology, #obesity, and #Alzheimer’s disease. Sven predicts that ‘obesity is going to become one of the biggest drug categories’ , with the recent releases of weight loss drugs being launched by Danish drug maker #NovoNordisk and US #EliLilly, and ‘could unlock a more than $100 billion-a-year obesity market’ (Even Seigerman, analyst at BMO Capital Markets).  #Biogen and #EliLilly are currently paving the way for effective treatment for Alzheimer’s. Following successful clinical trials, the drug by Biogen has now been fully certified and will be launching this year. While this will be a slower launch than oncology or weight loss, Sven believes that this too will be a multi-billion-dollar new disease category. Find out more here: https://lnkd.in/eRNN7UZ6 Investments involve risks. The value of investments and income derived from them may go down as well as up and you may not receive back all the money which you invest. Past performance is no guarantee of future performance. 

At Melinta Therapeutics, our commitment is to provide innovative therapies to people impacted by acute and life-threatening illnesses. Our vision is that all people who need our therapies will receive them. During the recent NewYorkBIO Life Science Showcase at NYSE, I had the privilege of presenting our mission and highlighting Melinta's remarkable evolution over the past few years, positioning us as an exceptional platform for growth. This year, with a team of 145 dedicated employees and a global presence in 105 markets, we are achieving meaningful growth. But beyond these impressive figures, our focus remains on revolutionizing acute care delivery. Throughout our journey of growth and transformation, we’ve remained steadfast in our commitment to improving patient outcomes. The landscape of acute care is intricate and dynamic, with substantial challenges in launching and commercializing new therapies, coupled with a pressing clinical need for innovative solutions. Nevertheless, this past year has given me more hope than ever that positive changes are not only possible, but already happening. I have only to look at the extraordinary work Melinta has done in this space to prove it…and we’re just getting started. Thank you again to NewYorkBio Life Science Showcase for providing a platform to share Melinta’s vision and strategic direction. I can’t wait to see where next year takes us! #InnovativeTherapies #HealthcareTransformation #GlobalImpact #MelintaMilestones

🌟 𝗡𝗼𝘃𝗼 𝗡𝗼𝗿𝗱𝗶𝘀𝗸'𝘀 𝗛𝗲𝗺𝗹𝗶𝗯𝗿𝗮 𝗥𝗶𝘃𝗮𝗹 𝗔𝗰𝗵𝗶𝗲𝘃𝗲𝘀 𝗣𝗵𝗮𝘀𝗲 𝟯 𝗦𝘂𝗰𝗰𝗲𝘀𝘀, 𝗦𝗲𝘁𝘁𝗶𝗻𝗴 𝗦𝘁𝗮𝗴𝗲 𝗳𝗼𝗿 𝗕𝗹𝗼𝗰𝗸𝗯𝘂𝘀𝘁𝗲𝗿 𝗦𝗵𝗼𝘄𝗱𝗼𝘄𝗻 𝘄𝗶𝘁𝗵 𝗥𝗼𝗰𝗵𝗲💊 𝗜𝗻 𝗔𝗽𝗿𝗶𝗹 𝟮𝟬𝟮𝟰, Novo Nordisk is vying for Hemlibra from Roche. The Danish drugmaker's rival to the popular #hemophilia medicine reached its key endpoint in a phase 3 trial, paving the way for an application📃 for approval sometime before the end of the year.By using Mim8, a 💉bispecific #antibody that bridges Factor IXa and X to replace absent Factor VIII, Novo Nordisk is controlling bleeding in a manner similar to that of Roche's Hemlibra. According to Novo Nordisk, the #treatment💊 was well tolerated and safe; there were no recorded thromboembolic events or deaths during the trial. One area Novo Nordisk thought it might have an advantage is efficacy. More than 70% of individuals may no longer require treatment for bleeding while using Mim8. 𝗟𝗼𝗼𝗸 𝗮𝘁 𝗼𝘂𝗿 𝗖𝗼𝗿𝗿𝗲𝗹𝗮𝘁𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁 👉: https://bit.ly/3UPaDID #NovoNordisk #Roche #Haemophilia #Phase3Trials #ClinicalTrials #Hemlibra #prophecymarketinsights

Lupus Accelerating Breakthroughs Consortium (#LupusABC), convened by the LRA, celebrated its first anniversary meeting to highlight substantial progress and set forth future directions. The first-of-its-kind public-private partnership, Lupus ABC is uniting individuals with lupus and their advocates, industry, clinicians, researchers, and government representatives to identify and pursue the most effective ways to accelerate the development of urgently needed personalized treatments for people with #lupus.    Learn more about the meeting presentations and four exciting new projects underway to accelerate lupus drug development: https://bit.ly/LUPUSABC-24 #LupusResearch #LupusTreatments 

One year ago OrsoBio launched and was featured in Fierce Pharma. "OrsoBio is shouting its launch news from the rooftops. The new metabolic-disorder-focused biotech was so excited, it issued press releases announcing various asset acquisitions not once, not twice, not thrice but, well, four times. Four press releases. And that's not even counting the Nov. 1 announcement that the company had launched. While the press blitz may seem a little overzealous, here we are writing about it. So let’s unpack the breaking news. OrsoBio launched Tuesday with Mani Subramanian, M.D., in the CEO seat, and Rob Myers, M.D. serving as chief medical officer. Both are alums of Gilead, where they worked on liver diseases—Subramanian as senior vice president and therapeutic area head for liver diseases, while Myers oversaw clinical development in liver fibrosis. The company was incubated by Samsara BioCapital. The California venture capital firm also contributed to a $300 million round for inflammatory-disease-focused Acelyrin in September." We were the lucky agency hired to brand the company and help it go to market with a new website. Ladybugz Interactive Agency, Boston MA In June 2023 clinical trials started and OrsoBio announced today will be presenting its results for Phase 1... Exciting News for our client!!!! Did you know we have helped over 40 biotechs launch new websites in just the past two years? So fun!!!! #biotechclients #biotech #biotechmarketing #biotechagency

BioAge Labs' recent achievement of securing $170m in a Series D funding round marks a significant milestone in the development of therapeutics for obesity and metabolic diseases. This substantial financial backing from investors like Sofinnova Investments, RA Capital, Longitude Capital, and Cormorant Asset Management, demonstrates a strong commitment to advancing innovative solutions in the healthcare sector. The funding influx not only propels BioAge's progress towards Phase II clinical trials of its drug candidate, azelaprag, but also opens doors for collaborations with industry giants like Eli Lilly. The potential of azelaprag, an oral apelin receptor agonist, to enhance obesity treatment outcomes by synergizing with Eli Lilly's Zepbound is certainly promising. These developments present exciting opportunities for BioAge in reshaping the landscape of metabolic disease treatments. As a professional in the recruitment space, staying updated on such groundbreaking advancements can offer valuable insights. BioAge's focus on developing novel therapeutics for metabolic diseases through the lens of human ageing presents a unique perspective in the healthcare industry. This strategic approach not only aligns with the evolving needs of the healthcare sector but also underscores the importance of integrating cutting-edge research and innovation in addressing complex health challenges. In light of BioAge's recent successes, it's clear that the company's dedication to pioneering approaches in metabolic disease treatment resonates strongly with both investors and industry partners. This serves as a testament to the value of visionary thinking and collaboration in driving meaningful progress within the pharmaceutical landscape. #BioAge #HealthcareInnovation #MetabolicDiseases

Are you curious to know how a family-owned biotech start-up is revolutionizing the way we manage pain? The The Grunenthal Group, a Germany-based family-owned pharmaceutical firm, is disrupting traditional pain management solutions through innovative research and development strategies. Led by founder Herman-Shan Wirtz, the company is highly dedicated to discovering new ways to treat pain more effectively and efficiently, with less side effects compared to current therapies. Want to learn more? Check out the full story on our website! https://lnkd.in/ena_cUsN Stay tuned for more cutting-edge innovation news from the exciting world of European startups! #Biotech #Pharmaceuticals #Innovation #PainManagement #Startups #EUStartups